GlassScriptPhysician profile
Michael F Graham
NPI 1750341434
$2,724.69
in general payments reported to CMS, 2019-2025
34 companies · $434 in 2025
The $434 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $735 · 2020: $141 · 2021: $421 · 2022: $260 · 2023: $522 · 2024: $211 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,083 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,082.59 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $376.61 | 2019-2023 | Myrbetriq, Veozah |
| Janssen Biotech, INC. | $302.53 | 2019-2025 | Erleada |
| Pfizer INC. | $259.66 | 2019-2020 | |
| Metuchen Pharmaceuticals | $148.88 | 2019-2022 | |
| Axonics, INC. | $124.56 | 2021-2023 | Axonics |
| Endo USA, INC. | $118.08 | 2024-2025 | Xiaflex |
| Urogen Pharma, INC. | $110.16 | 2021 | |
| Sumitomo Pharma America, INC. | $102.30 | 2023-2025 | Gemtesa |
| Laborie Medical Technologies Corp. | $102.10 | 2023 | |
| Endo Pharmaceuticals INC. | $99.51 | 2020-2024 | Xiaflex, Aveed |
| C. R. Bard, INC. & Subsidiaries | $95.95 | 2019-2023 | Bard Urinary Drainage Bag |
| Myriad Genetic Laboratories, INC. | $87.90 | 2021-2023 | Prolaris |
| Teleflex LLC | $79.29 | 2025 | Urolift, Barrigel |
| Cook Medical LLC | $58.61 | 2019-2024 | Ncircle |
| Bayer Healthcare Pharmaceuticals INC. | $57.34 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $52.27 | 2019 | |
| Urovant Sciences INC | $48.79 | 2022 | |
| Rochester Medical Corporation | $47.46 | 2021-2022 | |
| 180 Medical, INC. | $45.60 | 2023-2024 | |
| Travere Therapeutics, INC. | $44.13 | 2019-2021 | |
| Olympus America INC. | $36.89 | 2020-2024 | Itind System |
| Boston Scientific Corporation | $30.08 | 2025 | Spaceoar Vue System - 10ml |
| Procept Biorobotics Corporation | $29.04 | 2025 | |
| Convatec INC. | $28.57 | 2023 | |
| Abbvie INC. | $28.41 | 2021 | |
| Dendreon Pharmaceuticals LLC | $28.38 | 2025 | Provenge |
| Novartis Pharmaceuticals Corporation | $27.26 | 2025 | |
| Coloplast Corp | $26.54 | 2025 | |
| Allergan, INC. | $25.00 | 2019 | |
| Therapeuticsmd, INC. | $24.37 | 2019 | |
| Agiliti Surgical, INC. | $23.66 | 2019 | |
| Antares Pharma, INC. | $19.49 | 2020 | |
| Medtronic, INC. | $19.48 | 2022 | |
| Tolmar, INC. | $15.79 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.